Drugs / LUTETIUM PSMA-R2
LUTETIUM PSMA-R2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03490838 | May 2018 → May 2021 | prostate neoplasm | Advanced Accelerator Applications | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUTETIUM PSMA-R2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068777 ↗ |
| Known as | 177Lu-PSMA-R2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03490838 ↗ |
| Known as | LU177-PSMA-R2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068777 ↗ |
| Known as | LUTETIUM LU-177 PSMA-R2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068777 ↗ |
| Known as | Lutetium-177 psma-r2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068777 ↗ |
| Modality | Other / unclassified | “radio-ligand therapy” NCT03490838 ↗ |